Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 3,387 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Advanced Solid Tumors
Interventions: RO7623066, Olaparib, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: REGN6569, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more

Conditions: Advanced Solid Tumor, Colorectal Cancer
Interventions: TORL-3-600; Drug
Lead sponsor: TORL Biotherapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Fullerton, California • Los Angeles, California • Denver, Colorado + 4 more

Conditions: Cancer
Interventions: SOR-C13; Drug
Lead sponsor: Soricimed Biopharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions: Selumetinib, MEDI4736, Tremelimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more

Conditions: Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma, Primary Peritoneal Carcinoma
Interventions: ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab; Drug
Lead sponsor: Ensem Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Neoplasms
Interventions: DSP-0509, DSP-0509, Pembrolizumab; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: Ezabenlimab, BI 754111; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more

Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions: AZD5363; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • West Hollywood, California + 8 more

Conditions: Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Interventions: ALE.P02, Pembrolizumab; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 5 more

Conditions: Solid Tumor
Interventions: Oraxol; Drug
Lead sponsor: Kinex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Aurora, Colorado • Baltimore, Maryland • Buffalo, New York

Conditions: Advanced Solid Tumors, Malignant Neoplasm
Interventions: MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent), Epinephrine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Solid Tumor
Interventions: STX-001, Keytruda®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more

Conditions: Advanced Solid Tumor
Interventions: BGB-15025, Tislelizumab, Carboplatin, Cisplatin, Pemetrexed, Oxaliplatin, Capecitabine, Paclitaxel, nab-paclitaxel; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New York, New York • Houston, Texas • San Antonio, Texas

Conditions: Solid Tumors
Interventions: IPI-504, docetaxel; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 5 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: PI3K-beta Inhibitor GSK2636771; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Interventions: ANS03; Drug
Lead sponsor: Avistone Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors Cancer, MSI-H Cancer
Interventions: NDI-219216; Drug
Lead sponsor: Nimbus Wadjet, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more

Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions: Tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions: Alisertib, Itraconazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: St Louis, Missouri • Oklahoma City, Oklahoma • Germantown, Tennessee + 1 more

Conditions: Advanced Solid Tumors
Interventions: VBC108; Drug
Lead sponsor: VelaVigo Bio Inc; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Duarte, California • Grand Rapids, Michigan • New York, New York + 2 more

Conditions: Advanced Solid Tumors
Interventions: ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel; Biological · Drug
Lead sponsor: AskGene Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Advanced Solid Tumors
Interventions: Talazoparib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 7 more

Conditions: Cancer, Lymphoma
Interventions: XL844, Gemcitabine; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Search by objective public record fields.

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

A KRAS Inhibitor in Participants With Advanced Solid Tumors

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies